Dasatinib induced pleural effusions - Reply

Main Article Content

Mohammad AJ Abdulla
Mohamed A Yassin




Download data is not yet available.
Abstract 199 | PDF Downloads 67


1. Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med. 2010 Jul;16(4):351-6.
2. Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci. 2009;338(5):414.
3. Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol. 2013;31(2):103. Epub 2012 Jul 19.
4. Kathula SK. Dasatinib in chronic myelogenous leukemia. N Engl J Med. 2006 Sep;355(10):1062; author reply 1063-4.
5. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116(2):377
6. Yassin MA, El-Ayoubi HR, Kamzoul RT. Efficacy and safety of Dasatinib 50 mg once daily dose in patients with chronic phase CML who failed IMATINIB. Blood. 2011;118:21.
7. Abdulla MA, Amer A, Nawaz Z, Abdullah AS, Al-Sabbagh A, Kohla S, Nashwan A, Yassin MA. An uncommon case of chronic myeloid leukemia with variant cytogenetic. Acta Biomed. 2018;89(3-s):28-32.

Most read articles by the same author(s)

1 2 > >>